Europe's drug regulator is adding a brain tumor warning to two widely used contraceptive hormones. The EMA's safety committee found that desogestrel and etonogestrel — found in pills, implants, and vaginal rings — carry a small but real increased risk of meningioma with prolonged use. Women with a history of meningioma are now advised not to use these contraceptives.
Europe's medicines watchdog is updating the safety labels on some of the most commonly used hormonal contraceptives. The European Medicines Agency (EMA) safety committee has concluded that products containing the synthetic progestins desogestrel (oral tablets) and etonogestrel (implants and vaginal rings) are associated with a small increased risk of meningioma — typically non-cancerous tumors that form in the membranes surrounding the brain and spinal cord — particularly with prolonged use.
The risk is compounded for women who have previously used other meningioma-linked progestogens such as cyproterone, nomegestrol, medroxyprogesterone, and chlormadinone. Going forward, product labels will list meningioma as a side effect of unknown frequency, and healthcare providers will be required to monitor patients for warning signs including vision changes, hearing loss, worsening headaches, and seizures.
By the Numbers:
Why it matters: While the absolute risk remains very low, this regulatory update has real clinical implications — particularly for women with a personal history of meningioma, who should now avoid these contraceptives entirely. HCPs prescribing desogestrel- or etonogestrel-based products should proactively counsel patients and stay alert to neurological symptoms.
